• Eiji Shibahashi, Kentaro Jujo, Ayano Yoshida, Emiko Kawakami, Yuichiro Minami, and Nobuhisa Hagiwara.
• Department of Cardiology, Tokyo Women's Medical University, Tokyo, Japan; Department of Cardiovascular Intervention, Tokyo Women's Medical University Medical Center East, Tokyo, Japan.
• Am. J. Med. Sci. 2021 Mar 1; 361 (3): 344-351.

BackgroundIntra-aortic balloon pumping (IABP) counterpulsation provides potent supports on hemodynamic status of patients with cardiogenic shock. However, only limited numbers of patients with acute heart failure (AHF) under collapsed hemodynamic status received such benefit of IABP. We aimed to evaluate the impact of the timing of IABP induction on clinical prognosis in AHF patients at very high risk.MethodsOf 404 consecutive AHF patients, 57 patients both with left ventricular ejection fraction (LVEF) <35% and systolic blood pressure on admission <100 mmHg were ultimately enrolled in this observational study. They were divided into 3 groups depending on IABP use; Early-IABP group (induction at ≤3 days after admission, n = 17), Late-IABP group (>3 days, n = 15) and No-IABP group (n = 25). The primary endpoint was a composite of in-hospital cardiovascular (CV) death and ventricular assisted device implantation.ResultsThis high-risk population was typically mid-age (60 years-old), 61% male, and 75% with chronic kidney disease, and its average LVEF was 24.7%. Clinical profiles on admission were comparable among 3 subgroups, except prehospital prescription rate of loop diuretics. During hospital stay, intravenous inotropes were significantly more frequently administered in the Late-IABP group than other 2 groups. The primary endpoint was developed in 17.6% of patients in the Early-IABP group, which was significantly lower than that in the Late-IABP group (53.3%, p = 0.034) and was comparable to the No-IABP group (40.0%, p = 0.12).ConclusionsEarly induction of IABP is one of the therapeutic options for improvement of in-hospital prognosis in AHF patients at very high risk.Copyright © 2020 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.

18 keywords...

hide…